Satavaptan

Satavaptan
Clinical data
ATC code	none;
Identifiers
	IUPAC name N-(tert-butyl)-4-{[(1s,4s)-5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro[cyclohexane-1,3'-indol]-1'(2'H)-yl]sulfonyl}-3-methoxybenzamide;
CAS Number	185913-78-4 ;
PubChem CID	9810773;
ChemSpider	32699105 ;
UNII	AJS8S3P31H;
ECHA InfoCard	100.211.853
Chemical and physical data
Formula	C33H45N3O8S
Molar mass	643.80 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1COCCN1CCO[C@H]2CC[C@](CC2)3c4cc(OCC)ccc4N(C3=O)S(=O)(=O)c5ccc(cc5OC)C(=O)NC(C)(C)C;
	InChI InChI=1S/C33H45N3O8S/c1-6-43-25-8-9-27-26(22-25)33(13-11-24(12-14-33)44-20-17-35-15-18-42-19-16-35)31(38)36(27)45(39,40)29-10-7-23(21-28(29)41-5)30(37)34-32(2,3)4/h7-10,21-22,24H,6,11-20H2,1-5H3,(H,34,37)/t24-,33+ ; Key:QKXJWFOKVQWEDZ-VCCCEUOBSA-N ;
	(what is this?) (verify)

Satavaptan (INN; developmental code name SR121463, former tentative brand name Aquilda) is a vasopressin-2 receptor antagonist^[1] which was investigation by Sanofi-Aventis and was under development for the treatment of hyponatremia. It was also being studied for the treatment of ascites.^[2] Development was discontinued in 2009.^[3]

References

^ Soupart A, Gross P, Legros JJ, Alföldi S, Annane D, Heshmati HM, Decaux G (November 2006). "Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist". Clinical Journal of the American Society of Nephrology. 1 (6): 1154–60. doi:10.2215/CJN.00160106. PMID 17699341.
^ Ginès P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D (July 2008). "Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial". Hepatology. 48 (1): 204–13. doi:10.1002/hep.22293. PMID 18508290.
^ "Satavaptan". Adis Insight. Springer Nature Switzerland AG.

This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it.

[pmid17699341-1] Soupart A, Gross P, Legros JJ, Alföldi S, Annane D, Heshmati HM, Decaux G (November 2006). "Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist". Clinical Journal of the American Society of Nephrology. 1 (6): 1154–60. doi:10.2215/CJN.00160106. PMID 17699341.

[pmid18508290-2] Ginès P, Wong F, Watson H, Milutinovic S, del Arbol LR, Olteanu D (July 2008). "Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial". Hepatology. 48 (1): 204–13. doi:10.1002/hep.22293. PMID 18508290.

[AdisInsight-3] "Satavaptan". Adis Insight. Springer Nature Switzerland AG.

[1]

[2]

[3]

Clinical data

ATC code	none
Identifiers
IUPAC name N-(tert-butyl)-4-{[(1s,4s)-5'-ethoxy-4-(2-morpholin-4-ylethoxy)-2'-oxospiro[cyclohexane-1,3'-indol]-1'(2'H)-yl]sulfonyl}-3-methoxybenzamide
CAS Number	185913-78-4^Y
PubChem CID	9810773
ChemSpider	32699105^N
UNII	AJS8S3P31H
ECHA InfoCard	100.211.853
Chemical and physical data
Formula	C₃₃H₄₅N₃O₈S
Molar mass	643.80 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES C1COCCN1CCO[C@H]2CC[C@](CC2)3c4cc(OCC)ccc4N(C3=O)S(=O)(=O)c5ccc(cc5OC)C(=O)NC(C)(C)C
InChI InChI=1S/C33H45N3O8S/c1-6-43-25-8-9-27-26(22-25)33(13-11-24(12-14-33)44-20-17-35-15-18-42-19-16-35)31(38)36(27)45(39,40)29-10-7-23(21-28(29)41-5)30(37)34-32(2,3)4/h7-10,21-22,24H,6,11-20H2,1-5H3,(H,34,37)/t24-,33+^N Key:QKXJWFOKVQWEDZ-VCCCEUOBSA-N^N
^NY (what is this?) (verify)

Satavaptan

References

€4.95